• Research Tree
  • Features
  • Pricing
  • Events
  • Reg.News
  • Short Interest
  • Explore Content
    • Explore

      • Providers
        • Providers

          • Free/Commissioned
          • High Net Worth Offering
          • Institutional Offering

          Free/Commissioned

          Research that is free to access for all investors. Companies commission these providers to write research about them.

          View Research

          What is our Main Bundle Offering?

          Brokers who write research on their corporate clients and make it available through our main bundle offering.

          View Research

          What is Institutional?

          Research that is paid for directly by asset managers. Only accessible to institutional investors permissioned for access.

          View Research
      • Regions
        • Regions

          • UK
          • Rest of EMEA
          • N America
          • APAC
          • LatAm
      • Exchanges
        • Exchanges

          • Aquis Apex
          • Australian Securities Exchange
          • Canadian Securities Exchange
          • Euronext Paris
          • London Stock Exchange (domestic)
          • SIX Swiss Exchange
      • Sectors
        • Sector Coverage

          • Building & Construction
          • Discretionary Personal Goods
          • Discretionary Retail
          • Energy
          • Health
          • Investment Trusts
          • Media
          • Resources
          • Technology
      • Small / Large Cap
        • Small / Large Cap

          • UK100
          • UK250
          • UK Smallcap
          • UK Other Main Markets
          • Other
  • Login
  • Sign Up
LIVE

Event in Progress:

Join Here ×

working
  • 26 Feb 2025

Nutrien 4Q24: Strong Volumes and Lower Costs Support EBITDA


Nutrien Ltd. (NTR:TSE) | 0 0 0.0%


  • Hypothesis Research
    • Marina Alekseenkova

    • 5 pages


 

 Nutrien reported net earnings of $118mn, a 33% YoY decline, and adjusted EBITDA of $1,055mn, down 2% YoY in 4Q24. Revenue decreased 10% YoY to $5,079mn. In FY2024, revenue decreased 11% YoY to $25,972mn, with Adjusted EBITDA at $5,355mn (down 12% YoY), and net earnings at $700mn (down 45% YoY). Nutrien’s Retail sales fell 9.2% YoY to $3,179mn, primarily due to a 10.2% YoY drop in crop nutrients sales volumes to 2.57mt in 4Q. The gross margin of retail sales increased by 5.9% YoY in 4Q, while the international gross margin per ton declined by 31.5% YoY. Retail sales volumes decreased 3% YoY to 12.649mt in FY24. However, the total retail gross margin improved 4% YoY due to lower expenses and higher crop protection and seed margins. Retail Adjusted EBITDA reached $1,696mn in FY24, exceeding the guidance of $1.5-1.6bn. The Potash segment reported a 30.9% YoY decrease in net sales to $536mn in 4Q, driven by a 17.4% YoY decline in the average potash price. Potash production volumes fell 0.5% YoY in 4Q but increased 9% YoY to 14.205mt in FY24. Total potash sales for FY24 declined 20% YoY due to a 24% drop in potash price. Nitrogen sales volumes rose 6.6% YoY in 4Q24 and 3% YoY in FY24. The average nitrogen price increased 1.9% YoY in 4Q but declined 12% YoY in FY24. Nitrogen sales grew 6% YoY to $1,013mn in 4Q but declined 11% YoY to $3,745mn in FY24. The phosphate segment reported a 17% YoY decline in net sales to $1,657mn. In 4Q, net sales were $414mn, down 22.3% YoY primarily due to lower quarterly sales volumes. The company is focusing on reducing inventory levels, particularly in Brazil. The average phosphate price increased 7% YoY in 4Q and 3% YoY in FY24. Since early 2018, the company has increased its quarterly dividend by 36% to $0.545 per share. In 2H24, Nutrien repurchased 3.9mn shares for a total of $190mn and acquired 1.9mn shares in 2025 for $96mn as of February 18.  Nutrien expects Retail Adj EBITDA to range between $1.65bn and $1.85bn in FY25, compared to $1.696bn in FY24. Potash sales volumes are projected to be between 13.6 and 14.4mt in 2025, compared to 13.9mt in 2024. Nitrogen sales volumes are expected to reach 10.7-11.2mt, up from 10.6mt in 2024. Phosphate sales volumes are anticipated to range from 2.35mt to 2.55mt, down from 2.43mt last year. The guidance assumes higher operating rates for nitrogen and potash, with lower phosphate production in 1H25, followed by improved operating rates in 2H25. The company maintains its capex target of $2.0-2.1bn for 2025, in line with previous announcements. Nutrien expects strong global potash shipments, projected at 71-75mt in 2025, compared to 72.5mt in 2024. The company anticipates stronger prices in 2025, driven by robust demand and affordability. The anticipated Canadian tariff on potash could impact the prices for US customers. Increased capacity, improved gas utilization, and enhanced cost control are expected to contribute to volume and margin growth in 2025-26.  We have updated our forecasts and remain cautiously optimistic about the prospects for 2025, as demand for nutrients remains robust. The global supply of potash has been at historically high levels over the last two years, making it difficult to anticipate significantly stronger prices. While the sanctions against Russia and Belarus may change, supply from both countries has already recovered to pre-war levels. The nitrogen segment remains strong, with some European production capacities shut down due to higher gas costs. However, new capacities coming online are expected to replace older ones, keeping the market balanced. As a result, fertilizer affordability is likely to support the deliveries. We have updated our DCF-based 12-month price target to US$61.1 from US$ 57.1 and maintain a ‘Buy’ rating.

Sign up for free to access

Get access to the latest equity research in real-time from 12 commissioned providers.

Get access to the latest equity research in real-time from 12 commissioned providers.


Get Started
Already a member? Log in here
See all the research we have on this company.

Nutrien 4Q24: Strong Volumes and Lower Costs Support EBITDA


Nutrien Ltd. (NTR:TSE) | 0 0 0.0%


  • Published: 26 Feb 2025
  • Author: Marina Alekseenkova
  • Pages: 5
  • Hypothesis Research


 Nutrien reported net earnings of $118mn, a 33% YoY decline, and adjusted EBITDA of $1,055mn, down 2% YoY in 4Q24. Revenue decreased 10% YoY to $5,079mn. In FY2024, revenue decreased 11% YoY to $25,972mn, with Adjusted EBITDA at $5,355mn (down 12% YoY), and net earnings at $700mn (down 45% YoY). Nutrien’s Retail sales fell 9.2% YoY to $3,179mn, primarily due to a 10.2% YoY drop in crop nutrients sales volumes to 2.57mt in 4Q. The gross margin of retail sales increased by 5.9% YoY in 4Q, while the international gross margin per ton declined by 31.5% YoY. Retail sales volumes decreased 3% YoY to 12.649mt in FY24. However, the total retail gross margin improved 4% YoY due to lower expenses and higher crop protection and seed margins. Retail Adjusted EBITDA reached $1,696mn in FY24, exceeding the guidance of $1.5-1.6bn. The Potash segment reported a 30.9% YoY decrease in net sales to $536mn in 4Q, driven by a 17.4% YoY decline in the average potash price. Potash production volumes fell 0.5% YoY in 4Q but increased 9% YoY to 14.205mt in FY24. Total potash sales for FY24 declined 20% YoY due to a 24% drop in potash price. Nitrogen sales volumes rose 6.6% YoY in 4Q24 and 3% YoY in FY24. The average nitrogen price increased 1.9% YoY in 4Q but declined 12% YoY in FY24. Nitrogen sales grew 6% YoY to $1,013mn in 4Q but declined 11% YoY to $3,745mn in FY24. The phosphate segment reported a 17% YoY decline in net sales to $1,657mn. In 4Q, net sales were $414mn, down 22.3% YoY primarily due to lower quarterly sales volumes. The company is focusing on reducing inventory levels, particularly in Brazil. The average phosphate price increased 7% YoY in 4Q and 3% YoY in FY24. Since early 2018, the company has increased its quarterly dividend by 36% to $0.545 per share. In 2H24, Nutrien repurchased 3.9mn shares for a total of $190mn and acquired 1.9mn shares in 2025 for $96mn as of February 18.  Nutrien expects Retail Adj EBITDA to range between $1.65bn and $1.85bn in FY25, compared to $1.696bn in FY24. Potash sales volumes are projected to be between 13.6 and 14.4mt in 2025, compared to 13.9mt in 2024. Nitrogen sales volumes are expected to reach 10.7-11.2mt, up from 10.6mt in 2024. Phosphate sales volumes are anticipated to range from 2.35mt to 2.55mt, down from 2.43mt last year. The guidance assumes higher operating rates for nitrogen and potash, with lower phosphate production in 1H25, followed by improved operating rates in 2H25. The company maintains its capex target of $2.0-2.1bn for 2025, in line with previous announcements. Nutrien expects strong global potash shipments, projected at 71-75mt in 2025, compared to 72.5mt in 2024. The company anticipates stronger prices in 2025, driven by robust demand and affordability. The anticipated Canadian tariff on potash could impact the prices for US customers. Increased capacity, improved gas utilization, and enhanced cost control are expected to contribute to volume and margin growth in 2025-26.  We have updated our forecasts and remain cautiously optimistic about the prospects for 2025, as demand for nutrients remains robust. The global supply of potash has been at historically high levels over the last two years, making it difficult to anticipate significantly stronger prices. While the sanctions against Russia and Belarus may change, supply from both countries has already recovered to pre-war levels. The nitrogen segment remains strong, with some European production capacities shut down due to higher gas costs. However, new capacities coming online are expected to replace older ones, keeping the market balanced. As a result, fertilizer affordability is likely to support the deliveries. We have updated our DCF-based 12-month price target to US$61.1 from US$ 57.1 and maintain a ‘Buy’ rating.

More Content

More Content

Nutrien1Q25: Robust Potash Volumes with QoQ Price Improvement

Companies: Nutrien Ltd.

Hypothesis Research

Nutrien 1Q23: prices down to mid-cycle averages

Companies: Nutrien Ltd.

Hypothesis Research

Nutrien 2Q24: higher operating rates and lower costs

Companies: Nutrien Ltd.

Hypothesis Research

Nutrien 2Q23: guidance downgraded but the demand is promising

Companies: Nutrien Ltd.

Hypothesis Research

Nutrien 1Q24: company update

Companies: Nutrien Ltd.

Hypothesis Research
Research Tree
Useful Links
  • Features
  • Pricing
  • RNS/Newswires Feeds
  • Providers Hub
  • Company Hub
  • Stock Pick League
  • Chrome Extension
  • iOS and Android Apps
  • LLM Feed
Account
  • Login
  • Join Now
  • Contact
  • Follow us on Linkedin
  • Follow us on X

© Research Tree 2025

  • Apple Store
  • Play Store
  • Terms of Service
  • Privacy Policy and Statement on Cookies

Research Tree will never share your details with third parties for marketing purposes. Research Tree distributes research documents that have been produced and approved by Financial Conduct Authority (FCA) Authorised & Regulated firms as well as relevant content from non-authorised sources, who are not regulated but the information is in the public domain. For the avoidance of doubt Research Tree is not giving advice, nor has Research Tree validated any of the information.

Research Tree is an Appointed Representative of Sturgeon Ventures which is Authorised and Regulated by the Financial Conduct Authority.

Top
  • Home
  • Features
  • Pricing
  • Event Hub
  • Reg.News
  • Short Interest Tracker
  • Explore Content
    • Regions
      • UK
      • Rest of EMEA
      • N America
      • APAC
      • LatAm
    • Exchanges
      • Aquis Apex
      • Australian Securities Exchange
      • Canadian Securities Exchange
      • Euronext Paris
      • London Stock Exchange (domestic)
      • SIX Swiss Exchange
    • Sectors
      • Automobile Industry
      • Banks
      • Building & Construction
      • Chemicals
      • Discretionary Personal Goods
      • Discretionary Retail
      • Energy
      • ETFs
      • Financial Services
      • Food & Drink
      • Food Production
      • Health
      • Household Goods & DIY
      • Industrial Equipment, Goods & Services
      • Insurance & Reinsurance
      • Investment Trusts
      • Leisure, Tourism & Travel
      • Media
      • Open-ended Funds
      • Other
      • Real Estate
      • Resources
      • Staple Retail
      • Technology
      • Telecoms
      • Trusts, ETFs & Funds
      • Utilities
    • Small / Large Cap
      • UK100
      • UK250
      • UK Smallcap
      • UK Other Main Markets
      • Other
    • Private/EIS
      • EIS Single Company
      • EIS/SEIS Funds
      • IHT Products
      • SEIS Single Company
      • VCT Funds
  • Providers
    • Free/Commissioned
      • Actinver
      • Actio Advisors
      • Asset TV
      • Astris Advisory
      • Atrium Research
      • Baden Hill
      • BlytheRay
      • BNP Paribas Exane - Sponsored Research
      • Bondcritic
      • Brand Communications
      • Brokerlink
      • BRR Media
      • Calvine Partners
      • Capital Access Group
      • Capital Link
      • Capital Markets Brokers
      • Cavendish
      • Checkpoint Partners
      • Clear Capital Markets
      • Couloir Capital
      • Doceo
      • Edison
      • Engage Investor
      • Equity Development
      • eResearch
      • First Equity
      • Five Minute Pitch TV
      • focusIR
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • goetzpartners securities Limited
      • Golden Section Capital
      • GreenSome Finance
      • GSBR Research
      • H2 Radnor
      • Hardman & Co
      • Holland Advisors
      • Hypothesis Research
      • InterAxS Global
      • Kepler | Trust Intelligence
      • London Stock Exchange
      • Longspur Clean Energy
      • Mello Events
      • Messari Research
      • MUFG Corporate Markets IR
      • Nippon Investment Bespoke Research UK
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Optimo Capital
      • Panmure Liberum
      • Paul Scott
      • Peel Hunt
      • PIWORLD / Progressive
      • Proactive
      • Progressive Equity Research
      • Quantum Research Group
      • QuotedData
      • Research Dynamics
      • Research Tree
      • Resolve Research
      • SEAL Advisors Ltd
      • ShareSoc
      • Shore Capital
      • Sidoti & Company
      • Small Cap Consumer Research LLC
      • StockBox
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Edge Group
      • The Life Sciences Division
      • Trinity Delta
      • Turner Pope Investments
      • UK Investor Group
      • ValueTrack
      • Vox Markets
      • VRS International S.A. - Valuation & Research Specialists (VRS)
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Yaru Investments
      • Yellowstone Advisory
      • Zacks Small Cap Research
      • Zeus Capital
    • High Net Worth Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Acquisdata
      • Align Research
      • Allenby Capital
      • AlphaValue
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • Baptista Research
      • BNP Paribas Exane - Sponsored Research
      • Canaccord Genuity
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • First Berlin
      • First Equity
      • First Sentinel
      • Greenwood Capital Partners
      • Hannam & Partners
      • Hybridan
      • Kemeny Capital
      • Longspur Clean Energy
      • Louis Capital
      • Magnitogorsk Iron and steel works
      • Medley Global Advisors
      • Northland Capital Partners
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • QuotedData Professional
      • Shard Capital
      • ShareSoc
      • Shore Capital
      • Singer Capital Markets
      • SP Angel
      • Stanford Capital Partners
      • Stifel FirstEnergy
      • Stockdale Securities
      • Tamesis Partners
      • Tennyson Securities
      • The Life Sciences Division
      • Turner Pope Investments
      • VSA Capital
      • Whitman Howard
      • Yellowstone Advisory
      • Zeus Capital
    • Institutional Offering
      • Fox-Davies Capital
      • ABG Sundal Collier
      • ACF Equity Research
      • Allenby Capital
      • Alternative Resource Capital
      • Arctic Securities
      • Arden Partners
      • Auctus Advisors
      • BNP Paribas Exane
      • Bondcritic
      • Canaccord Genuity
      • Capital Access Group
      • Capital Link
      • Cavendish
      • Couloir Capital
      • Degroof Petercam
      • Dowgate Capital
      • Edison
      • First Berlin
      • First Equity
      • First Sentinel
      • Five Minute Pitch TV
      • Fundamental Research Corp
      • Galliano’s Latin Notes
      • GBC AG
      • Golden Section Capital
      • Goodbody
      • Greenwood Capital Partners
      • Hannam & Partners
      • Holland Advisors
      • Hybridan
      • InterAxS Global
      • Investec Bank
      • Kepler | Trust Intelligence
      • Numis
      • NuWays
      • OAK Securities
      • Oberon Capital
      • Panmure Liberum
      • Peel Hunt
      • QuotedData
      • QuotedData Professional
      • Research Dynamics
      • Research Tree
      • Shard Capital
      • Shore Capital
      • Sidoti & Company
      • Singer Capital Markets
      • Small Cap Consumer Research LLC
      • SP Angel
      • Stanford Capital Partners
      • Stifel
      • StockBox
      • Tamesis Partners
      • Tennyson Securities
      • The AIC
      • The Business Magazine Group
      • The Life Sciences Division
      • ValueTrack
      • Velocity Trade
      • VSA Capital
      • Winterflood Securities
      • World Platinum Investment Council
      • Zacks Small Cap Research
      • Zeus Capital
  • Contact
  • Sign Up
  • Sign In